我院433例药品不良反应报告分析
x
请在关注微信后,向客服人员索取文件
篇名: | 我院433例药品不良反应报告分析 |
TITLE: | |
摘要: | 目的:探讨我院药品不良反应(ADR)发生的临床特点、规律,为临床合理、安全用药提供参考。方法:对广东省ADR监测中心收录的我院2014年1月-2015年6月的ADR报告进行整理、统计与分析。结果:433例发生ADR的患者中,男性185例(42.73%),女性248例(57.27%),男女比例为1 ∶ 1.34。中青年(20~59岁)患者ADR发生率较高(71.59%),且男性明显少于女性(1 ∶ 1.37)。ADR给药途径以静脉滴注(48.04%)和口服给药(41.57%)为主。抗感染药物引发ADR的例数最多(167例,38.57%),其中以头孢菌素类为主(64.07%)。ADR累及器官/系统以消化系统损害(262例次,36.19%)和皮肤及其附件损害(237例次,32.73%)为主。严重的ADR主要涉及抗感染药物和抗肿瘤药物。结论:临床医务人员应加强头孢菌素类抗菌药物和抗肿瘤药物的ADR监测,谨慎选择给药途径。 |
ABSTRACT: | ABSTRACT OBJECTIVE: To investigate the clinical characteristics and regularity of adverse drug reaction (ADR), and to provide reference for rational and safe drug use in the clinic. METHODS: ADR reports collected from our hospital by Guangdong ADR Monitoring Center during Jan. 2014 to June. 2015 were summarized and analyzed statistically. RESULTS: Of 433 ADR cases, there were 185 male cases (42.73%) and 248 female cases (57.27%), with ratio of 1 ∶ 1.34. The incidence of ADR was in high level (71.59%) in young and middle-aged patients (20-59 year-old); that of male was significantly lower than that of female (1 ∶ 1.37). ADR cases caused by intravenous drip (48.04%) and oral administration (41.57%) were most common. The most ADR cases were related with anti-infective drugs (167 cases, 38.57%), mainly were related with cephalosporins (64.07%). Organs/systems involved in ADR were main the damages of gastrointestinal system (262 cases, 36.19%) and the lesion of skin and appendants (237 cases, 32.73%). The serious ADR was mainly induced by anti-infective and anti-tumor drugs. CONCLUSIONS: Clinical medical personnel should strengthen the ADR monitoring of cephalosporin antibiotics and anti-tumor drug, and select route of administration carefully. |
期刊: | 2016年第27卷第26期 |
作者: | 余文浩,李玉珍,曾繁涛,刘君波,陈旎旎,徐小英 |
AUTHORS: | U Wenhao,LI Yuzhen,ZENG Fantao,LIU Junbo,CHEN Nini,XU Xiaoying |
关键字: | 药品不良反应;分析;合理用药 |
KEYWORDS: | Adverse drug reaction; Analysis; Rational drug use |
阅读数: | 236 次 |
本月下载数: | 4 次 |
* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!